ACELYRIN, INC Total Liabilities 2022-2025 | SLRN

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

ACELYRIN, INC total liabilities from 2022 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.

ACELYRIN, INC Total Liabilities 2022-2025 | SLRN

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

ACELYRIN, INC total liabilities from 2022 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$247.9B
Amgen (AMGN)	$155B
Gilead Sciences (GILD)	$141.4B
Vertex Pharmaceuticals (VRTX)	$99.8B
Bristol Myers Squibb (BMY)	$96.9B
GSK (GSK)	$81.3B
CSL (CSLLY)	$67.8B
Regeneron Pharmaceuticals (REGN)	$62.2B
Alnylam Pharmaceuticals (ALNY)	$59.5B
Argenex SE (ARGX)	$43.3B
Insmed (INSM)	$28.4B
BioNTech SE (BNTX)	$24.8B
Royalty Pharma (RPRX)	$21B
Biogen (BIIB)	$20B
Incyte (INCY)	$16.6B
Genmab (GNMSF)	$16B
Genmab (GMAB)	$15.9B
Illumina (ILMN)	$15.3B
Ascendis Pharma (ASND)	$11.8B
BioMarin Pharmaceutical (BMRN)	$11.3B
Swedish Orphan Biovitrum (BIOVF)	$10.9B
QIAGEN (QGEN)	$10.7B
Exelixis (EXEL)	$10.4B
Moderna (MRNA)	$9.8B
Verona Pharma American Depositary Share (VRNA)	$9.1B
Exact Sciences (EXAS)	$8.8B
Bio-Techne Corp (TECH)	$8.8B
Halozyme Therapeutics (HALO)	$8.6B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$8.2B